• 
  Marion Dhooge, Stéphanie Baert-Desurmont, Carole Corsini, Olivier Caron, Nadine Andrieu, et al.. National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract. European Journal of Medical Genetics, Elsevier, 2020, 63 (12), pp.104080. ⟨10.1016/j.ejmg.2020.104080⟩. ⟨inserm-03182974⟩
• 
  François Chevalier, Dounia Houria Hamdi, Charlotte Lepleux, Mihaela Temelie, Anaïs Nicol, et al.. High LET Radiation Overcomes In Vitro Resistance to X-Rays of Chondrosarcoma Cell Lines. Technology in Cancer Research and Treatment, Adenine Press, 2019, 18, pp.153303381987130. ⟨10.1177/1533033819871309⟩. ⟨hal-02333914⟩
• 
  Paul Lesueur, François Chevalier, Jean-Baptiste Austry, Waisse Waissi, Hélène Burckel, et al.. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget, Impact journals, 2017, 8 (40), ⟨10.18632/oncotarget.19079⟩. ⟨hal-02493848⟩
• 
  Dounia Houria Hamdi, Charlotte Lepleux, Agnès Nicolle, Guillaume Varès, Paul Lesueur, et al.. High LET Radiation Overcomes in vitro Resistance to X-rays of Chondrosarcoma Cell Lines. ENLIGHT Annual Meeting and Training 2019, Jul 2019, Caen, France. ⟨hal-03144579⟩
• 
  Guillaume Vogin, Liza Hettal, Clarisse Bartau, Juliette Thariat, Marie-Virginie Claeys, et al.. Cranial organs at risk delineation: heterogenous practices in radiotherapy planning. Radiation Oncology, BioMed Central, 2021, 16, pp.26. ⟨10.1186/s13014-021-01756-y⟩. ⟨hal-03134498⟩
• 
  Steven Le Gouill, Hervé Ghesquieres, Lucie Obéric, Franck Morschhauser, Herve Tilly, et al.. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2020, ⟨10.1182/blood.2020008750⟩. ⟨hal-03122586⟩
• 
  Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, et al.. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. BMC Cancer, BioMed Central, 2020, 20 (1), pp.352. ⟨10.1186/s12885-020-06841-1⟩. ⟨hal-03130294⟩
• 
  Astrid Lièvre, Anthony Turpin, Isabelle Ray-Coquard, Karine Le Malicot, Juliette Thariat, et al.. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).. European Journal of Cancer, Elsevier, 2020, 141, pp.62-81. ⟨10.1016/j.ejca.2020.09.035⟩. ⟨hal-02998283⟩
• 
  J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, et al.. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. Radiotherapy and Oncology, Elsevier, 2020, 154 (227-234), ⟨10.1016/j.radonc.2020.09.036⟩. ⟨hal-02954534⟩
• 
  Christian Pfister, Valentin Harter, Yves Allory, François Radvanyi, Stéphane Culine, et al.. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemporary Clinical Trials Communications, Elsevier, 2020, 17, pp.100536. ⟨10.1016/j.conctc.2020.100536⟩. ⟨hal-02909542⟩

53